U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06864481) titled 'Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis' on Feb. 25.
Brief Summary: Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors. While effective, they can cause immune-related side effects, including liver inflammation (ICI-induced hepatitis or CHILI), which affects up to 25% of patients. Severe cases requiring treatment discontinuation are rare but challenging to manage.
Study Objective This multicenter prospective study aims to better understand CHILI, its clinical patterns, treatment response, and risk of recurrenc...